Tyra Biosciences, Inc. (NASDAQ:TYRA) Director Sells $309,300.00 in Stock

Tyra Biosciences, Inc. (NASDAQ:TYRA) Director Gilla Kaplan sold 30,000 shares of Tyra Biosciences stock in a transaction that occurred on Thursday, June 12th. The shares were sold at an average price of $10.31, for a total transaction of $309,300.00. Following the sale, the director now owns 59,623 shares in the company, valued at $614,713.13. This represents a 33.47% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Gilla Kaplan also recently made the following trade(s):

• On Monday, June 16th, Gilla Kaplan sold 6,814 shares of Tyra Biosciences stock. The shares were sold at an average price of $10.38, for a total transaction of $70,729.32.
• On Friday, June 13th, Gilla Kaplan sold 15,000 shares of Tyra Biosciences stock. The stock was sold at an average price of $10.31, for a total transaction of $154,650.00.

Tyra Biosciences Stock Performance

TYRA opened at $9.50 on Thursday. The company has a market capitalization of $504.36 million, a P/E ratio of -5.83 and a beta of 1.07. The company has a 50-day moving average of $9.70 and a 200-day moving average of $11.85. Tyra Biosciences, Inc. has a 1-year low of $6.42 and a 1-year high of $29.60.

Tyra Biosciences (NASDAQ:TYRA) last announced its quarterly earnings data on Thursday, May 8th. The company reported ($0.47) earnings per share for the quarter, beating the consensus estimate of ($0.49) by $0.02. As a group, sell-side analysts expect that Tyra Biosciences, Inc. will post -1.57 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in TYRA. Alta Partners Management Company L.P. bought a new position in Tyra Biosciences during the fourth quarter worth $56,716,000. Boxer Capital Management LLC bought a new stake in Tyra Biosciences during the fourth quarter valued at $28,185,000. Vestal Point Capital LP increased its stake in Tyra Biosciences by 190.9% during the first quarter. Vestal Point Capital LP now owns 2,879,829 shares of the company’s stock valued at $26,782,000 after purchasing an additional 1,889,829 shares during the last quarter. Farallon Capital Management LLC acquired a new stake in shares of Tyra Biosciences during the fourth quarter worth $13,914,000. Finally, Orbimed Advisors LLC lifted its position in shares of Tyra Biosciences by 91.3% in the 4th quarter. Orbimed Advisors LLC now owns 1,470,086 shares of the company’s stock worth $20,434,000 after buying an additional 701,448 shares during the last quarter. Institutional investors and hedge funds own 84.14% of the company’s stock.

Analyst Upgrades and Downgrades

TYRA has been the subject of a number of analyst reports. Wedbush reissued an “outperform” rating and issued a $30.00 price objective on shares of Tyra Biosciences in a research report on Friday, March 28th. Piper Sandler initiated coverage on Tyra Biosciences in a report on Wednesday, May 21st. They issued an “overweight” rating and a $33.00 price target for the company. Finally, HC Wainwright restated a “buy” rating and set a $30.00 price objective on shares of Tyra Biosciences in a research note on Monday, March 31st. Six equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus target price of $30.83.

Tyra Biosciences Company Profile

Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.